Erasca, Inc.
ERAS
शेयरों में रैंक
#3469
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
शेयर मूल्य
$14.03
मार्केट कैप
$4.91B
बदलाव (1 दिन)
-3.18%
बदलाव (1 वर्ष)
518.05%
देश
US
व्यापार Erasca, Inc. (ERAS)
श्रेणी
Healthcare
Erasca, Inc. (ERAS) के लिए स्टॉक मूल्य इतिहास
दिन का सबसे उच्च समापन मूल्य: $14.62 (2026-10-01 को)
दिन का सबसे निम्न समापन मूल्य: $19.40 (2021-07-01 को)
दिन का सबसे निम्न समापन मूल्य: $19.40 (2021-07-01 को)
Erasca, Inc. के स्टॉक मूल्य का इतिहास 2021 से 2026 तक
प्रत्येक वर्ष के अंत में स्टॉक मूल्य प्रदर्शन
| वर्ष | प्रदर्शन |
|---|---|
| 2026 (TTM) | 260.39% |
| 2025 | 24.72% |
| 2024 | 41.38% |
| 2023 | -63.49% |
| 2022 | -62.73% |
| 2021 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के स्टॉक मूल्य
| कंपनी | स्टॉक मूल्य | परिवर्तन 1व% | देश |
|---|---|---|---|
| $535.97 | 25.69% |
US
|
|
| $190.72 | 610.32% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $889.32 | 9.23% |
NL
|
